Roche Licenses Alzheimer’s Compounds from Memory Pharmaceuticals

doi:10.3833/pdr.v2002i27.1018

Pharma Deals Review, Vol 2002, No 27 (2002)

Roche Licenses Alzheimer’s Compounds from Memory Pharmaceuticals

Business Review Editor

Abstract

Roche has acquired an exclusive worldwide license from Memory Pharmaceuticals to develop promising compounds for Alzheimer’s disease in a deal worth up to US$150 M.

Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.